Point72 Asset Management L.P. Decreases Holdings in Sanofi (NASDAQ:SNY)

Point72 Asset Management L.P. cut its stake in Sanofi (NASDAQ:SNY) by 58.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 88,879 shares of the company’s stock after selling 122,609 shares during the quarter. Point72 Asset Management L.P.’s holdings in Sanofi were worth $5,122,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of SNY. Bank of New York Mellon Corp boosted its position in Sanofi by 19.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after buying an additional 1,370,232 shares during the last quarter. Barrow Hanley Mewhinney & Strauss LLC lifted its stake in shares of Sanofi by 113.8% in the second quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after acquiring an additional 3,164,092 shares in the last quarter. Envestnet Asset Management Inc. boosted its holdings in Sanofi by 8.2% in the second quarter. Envestnet Asset Management Inc. now owns 3,252,326 shares of the company’s stock valued at $157,803,000 after purchasing an additional 246,224 shares during the last quarter. Federated Hermes Inc. grew its stake in Sanofi by 26.5% during the 2nd quarter. Federated Hermes Inc. now owns 3,214,141 shares of the company’s stock valued at $155,950,000 after purchasing an additional 673,172 shares in the last quarter. Finally, Natixis Advisors LLC increased its holdings in Sanofi by 4.1% during the 3rd quarter. Natixis Advisors LLC now owns 2,874,193 shares of the company’s stock worth $165,640,000 after purchasing an additional 114,133 shares during the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

SNY stock opened at $48.46 on Monday. The stock’s 50 day simple moving average is $51.90 and its 200 day simple moving average is $52.11. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The firm has a market cap of $122.98 billion, a P/E ratio of 24.72, a P/E/G ratio of 1.22 and a beta of 0.58. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17.

Sanofi (NASDAQ:SNY) last issued its earnings results on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company had revenue of $13.44 billion for the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the prior year, the company earned $2.55 earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. As a group, equities research analysts predict that Sanofi will post 4.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Citigroup upgraded Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. StockNews.com downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Friday. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Sanofi currently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.